225 related articles for article (PubMed ID: 12723505)
21. Gemcitabine and acute myocardial infarction--a case report.
Bdair FM; Graham SP; Smith PF; Javle MM
Angiology; 2006; 57(3):367-71. PubMed ID: 16703198
[TBL] [Abstract][Full Text] [Related]
22. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
[TBL] [Abstract][Full Text] [Related]
24. Severe acute lung injury induced by gemcitabine.
Linskens RK; Golding RP; van Groeningen CJ; Giaccone G
Neth J Med; 2000 Jun; 56(6):232-5. PubMed ID: 10821980
[TBL] [Abstract][Full Text] [Related]
25. Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.
Tavil Y; Arslan U; Okyay K; Sen N; Boyaci B
Onkologie; 2007 May; 30(5):253-5. PubMed ID: 17460420
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Thatcher N; Jayson G; Bradley B; Ranson M; Anderson H
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-6-S8-12. PubMed ID: 9207309
[TBL] [Abstract][Full Text] [Related]
27. Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Neubauer MA; Reynolds CH; Joppert MG; Whitaker T; Ghaddar H; Marsland TA; Asmar L
Clin Lung Cancer; 2005 Jan; 6(4):245-9. PubMed ID: 15694017
[TBL] [Abstract][Full Text] [Related]
28. [A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].
Nagashima O; Tajima K; Ito J; Kajiyama Y; Shimanuki Y; Miura K; Sato K; Miyamoto H; Uekusa T; Suzuki T; Takahashi K; Fukuchi Y
Nihon Kokyuki Gakkai Zasshi; 2006 Mar; 44(3):215-9. PubMed ID: 16617866
[TBL] [Abstract][Full Text] [Related]
29. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Takada M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Fukuoka M
Cancer Chemother Pharmacol; 1998; 41(3):217-22. PubMed ID: 9443638
[TBL] [Abstract][Full Text] [Related]
30. Vasculitis due to gemcitabine.
Voorburg AM; van Beek FT; Slee PH; Seldenrijk CA; Schramel FM
Lung Cancer; 2002 May; 36(2):203-5. PubMed ID: 11955656
[TBL] [Abstract][Full Text] [Related]
31. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.
Gridelli C; Cigolari S; Gallo C; Manzione L; Ianniello GP; Frontini L; Ferraù F; Robbiati SF; Adamo V; Gasparini G; Novello S; Perrone F;
Lung Cancer; 2001; 31(2-3):277-84. PubMed ID: 11165408
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine-associated diffuse alveolar hemorrhage.
Carron PL; Cousin L; Caps T; Belle E; Pernet D; Neidhardt A; Capellier G
Intensive Care Med; 2001 Sep; 27(9):1554. PubMed ID: 11685353
[No Abstract] [Full Text] [Related]
33. [Favorable outcome of gemcitabine-induced acute respiratory distress syndrome].
Bonnichon A; Vedrine L; Aletti M; Le Moulec S; Borne M; Margery J; Bauduceau O; Fayolle M; Ceccaldi B
Rev Pneumol Clin; 2007 Dec; 63(6):379-83. PubMed ID: 18166944
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
35. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
36. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.
Lund B; Ryberg M; Petersen PM; Anderson H; Thatcher N; Dombernowsky P
Ann Oncol; 1994 Nov; 5(9):852-3. PubMed ID: 7848889
[No Abstract] [Full Text] [Related]
38. Gemcitabine-induced systemic capillary leak syndrome.
De Pas T; Curigliano G; Franceschelli L; Catania C; Spaggiari L; de Braud F
Ann Oncol; 2001 Nov; 12(11):1651-2. PubMed ID: 11822767
[TBL] [Abstract][Full Text] [Related]
39. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
40. Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer.
Yildiz R; Coskun U; Kaya AO; Ozturk B; Yaman E
Ann Pharmacother; 2007 May; 41(5):901-2. PubMed ID: 17405819
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
